|
Notification of cessation of securities - RAC
|
29 June 2023 at 10:15am
|
|
Proposed issue of securities - RAC
|
29 June 2023 at 10:15am
|
|
Initial Director's Interest Notice
|
29 June 2023 at 10:10am
|
|
Final Director's Interest Notice
|
29 June 2023 at 10:05am
|
|
Race Board Changes
|
29 June 2023 at 10:05am
|
|
Update - Notification of buy-back - RAC
|
22 June 2023 at 4:50pm
|
|
Race Completes On-Market Buy-Back Program
|
22 June 2023 at 4:50pm
|
|
Letter to Shareholders
|
15 June 2023 at 11:05am
|
|
Ceasing to be a substantial holder
|
15 May 2023 at 5:05pm
|
|
Cleansing Notice
|
12 May 2023 at 1:45pm
|
|
Application for quotation of securities - RAC
|
12 May 2023 at 1:40pm
|
|
Race appoints Dr Michelle Rashford Chief Medical Officer
|
9 May 2023 at 9:25am
|
|
Quarterly Activity Report & Appendix 4C
|
28 April 2023 at 10:10am
|
|
Race continues Board renewal - appoints new Chair
|
20 April 2023 at 9:50am
|
|
Race releases complete cardio-protection data & video
|
14 April 2023 at 9:35am
|
|
Race releases cardioprotection market potential data
|
4 April 2023 at 9:45am
|
|
Race Receives $1.48m R&D Tax Refund for Financial Year 2022
|
27 March 2023 at 11:55am
|
|
Final Director's Interest Notice - Dr Daniel Tillett
|
24 March 2023 at 6:40pm
|
|
Race Leadership Changes
|
24 March 2023 at 9:20am
|
|
Trading Halt
|
22 March 2023 at 10:35am
|
|
Pause in Trading
|
22 March 2023 at 10:25am
|
|
Race Executes Contracts to Commence Breast Cancer Trial
|
13 March 2023 at 9:35am
|
|
Replacement Appendix 3Y - Damian Clarke Bruce
|
3 March 2023 at 3:59pm
|
|
Appendix 3Y x 3
|
3 March 2023 at 3:30pm
|
|
Notification regarding unquoted securities - RAC
|
3 March 2023 at 3:00pm
|
|
New Collaboration to Understand Zantrene Cardioprotection
|
2 March 2023 at 12:55pm
|
|
Appendix 4D & Half-Year Financial Statements
|
27 February 2023 at 4:55pm
|
|
Results of Meeting
|
21 February 2023 at 11:20am
|
|
Appendix 3Y - Dr Daniel Tillett
|
7 February 2023 at 3:55pm
|
|
Cleansing Notice
|
2 February 2023 at 3:00pm
|
|
Application for quotation of securities - RAC
|
2 February 2023 at 2:55pm
|
|
Replacement Appendix 3X - Damian Clarke-Bruce
|
1 February 2023 at 2:30pm
|
|
Race Receives Cardioprotection Ethics Trial Approval
|
1 February 2023 at 9:50am
|
|
Appendix 3X - Damian Clarke-Bruce
|
1 February 2023 at 9:15am
|
|
Quarterly Activity Report & Appendix 4C
|
31 January 2023 at 11:30am
|
|
Letter to Shareholders, Notice of Meeting & Proxy Form
|
19 January 2023 at 5:00pm
|
|
Appendix 3Y - Dr Daniel Tillett
|
16 January 2023 at 6:10pm
|
|
December 2022 Preclinical & Clinical Programs Update
|
23 December 2022 at 9:25am
|
|
Race supports Study of Extramedullary AML
|
22 December 2022 at 11:20am
|
|
Appendix 3Y - Dr Daniel Tillett
|
21 December 2022 at 9:25am
|
|
Proposed issue of securities - RAC
|
14 December 2022 at 10:10am
|
|
Race Appoints Damian Clarke-Bruce as CEO & Managing Director
|
14 December 2022 at 9:55am
|
|
Ethics submission to commence cardioprotection trial
|
9 December 2022 at 10:30am
|
|
Appendix 3X - Danny Sharp
|
5 December 2022 at 10:30am
|
|
Proposed issue of securities - RAC
|
5 December 2022 at 10:30am
|
|
Danny Sharp appointed Independent Non-Executive Director
|
5 December 2022 at 10:15am
|
|
Constitution
|
24 November 2022 at 1:55pm
|
|
Results of Annual General Meeting
|
24 November 2022 at 1:50pm
|
|
Race 2022 AGM Presentations
|
24 November 2022 at 8:45am
|
|
Positive Pre-IND Guidance from FDA on Zantrene
|
23 November 2022 at 10:59am
|
Race Oncology